In this video (published June 22, 2023), Dr. Patrick Nemechek shares how he thinks about long COVID through the lens of chronic inflammation. Drawing from his prior career as an HIV clinician and researcher, he describes a pattern he believes is emerging in some people after COVID: ongoing inflammatory stress that persists because the intestinal tract is not fully recovering.
Throughout the discussion, Dr. Nemechek emphasizes a core theme: in his framework, many of the most serious downstream effects in both HIV and COVID are driven less by direct viral injury and more by inflammation and immune dysregulation. He uses simplified metaphors (such as different “branches” of the immune system) to explain how inflammatory signaling can become self-perpetuating.
How Dr. Nemechek links viral illness, gut barrier injury, and persistent immune activation
Dr. Nemechek begins by describing what he observed during years of HIV clinical work. In his explanation, HIV can generate an “intense amount of inflammation,” and that inflammatory state—not simply viral replication—was a major driver of immune system deterioration in untreated patients. He notes that, in some people, stopping HIV replication with medication did not necessarily bring inflammation down, and those patients tended to do poorly compared with patients whose inflammation decreased and whose immune system rebounded.
He then introduces a gut-centered hypothesis that he says is being found in a subset of patients who do not recover well: intestinal barrier disruption. He distinguishes between what is commonly described as “leaky gut” (where material leaks between the seams of adjacent intestinal cells) and a different pattern he describes in some cases—what he characterizes as “big holes” or “big gaps” at a microscopic level. In his telling, this allows a large volume of material to move into immune-rich tissue around the small intestine. He underscores that a large proportion of the immune system is positioned around the small intestine, so ongoing exposure there can sustain inflammatory stress.
Long COVID in this video: “long inflammation” driven by intestinal tract injury
Turning to COVID, Dr. Nemechek describes COVID as also killing through inflammation, but in a different way than HIV. In his explanation, COVID does not necessarily deplete immune function in the same manner; instead, the inflammatory chemicals released in COVID are what can trigger severe complications. He lists examples he attributes to inflammation, including blood clots in the lungs, lung damage, heart failure, kidney failure, brain-related damage, and nerve-related effects such as loss of smell.
What he finds “very interesting,” he says, is that COVID appears to show a similar gut-related phenomenon: microscopic holes in the intestinal tract, with material flowing into the immune system around the small intestine. In Dr. Nemechek’s clinical interpretation, this ongoing flow perpetuates “chronic inflammation,” and this is why some long-haulers “can’t recover.” He summarizes this with a clear statement of his framework: long COVID is essentially “long inflammation” (chronic inflammation), and the key is trying to fix the intestinal tract.
Clinical observations he shares: rifaximin and partial vs. strong recovery patterns
Within the limits of what he presents in the video, Dr. Nemechek offers a practical clinical observation: some long COVID patients “recover” or “improve some” when he uses rifaximin, which he describes as a way to help balance gut bacteria. He further notes that outcomes vary:
- Some patients, in his experience, “recovered great” with rifaximin alone.
- Another subset only partially recovered with rifaximin.
In Dr. Nemechek’s interpretation, the partial-response group may overlap with people who have more significant intestinal barrier disruption—what he described earlier as multiple microscopic holes with more extensive leakage into surrounding immune tissue. He frames this as a plausible reason for persistent inflammatory stress, rather than presenting it as settled proof.
Ongoing research he mentions: an amino acid approach to “fix” the intestinal tract
Dr. Nemechek also mentions active research he and colleagues are doing with a subset of patients, using a particular amino acid with the goal of improving intestinal tract integrity. He is explicit that he is not ready to share details: he says he does not yet have an answer or a dosing schedule and will not tell people what they are doing until he has something “meaningful.” He references this as an approach they used “back in the HIV days” and expresses cautious optimism that they may have something practical to share within a few months, while acknowledging uncertainty.
What this framework means for readers following long COVID discussions
This short update is best read as Dr. Nemechek’s snapshot of where his thinking and early clinical experience were at the time of recording. The key takeaways he emphasizes are (1) the centrality of chronic inflammation in long COVID, in his framework, and (2) the importance of the intestinal tract and gut-immune interface as a potential driver of persistent inflammatory activation in some patients.
Educational medical disclaimer: This article summarizes statements from a single video and reflects Dr. Nemechek’s clinical explanations and interpretations as presented there. It is not medical advice and is not a substitute for diagnosis or treatment by a licensed clinician. Do not start, stop, or change any medication or supplement based on this content; discuss symptoms and options with your healthcare professional.
